Detalhe da pesquisa
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38818978
2.
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
Ann Hematol
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38805036
3.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638723
4.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716957
5.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161453
6.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353388
7.
Targeting of GSK3ß promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Blood
; 119(10): 2335-45, 2012 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22262776
8.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924160
9.
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
Front Oncol
; 11: 739171, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34513714
10.
MTHFR polymorphisms involved in vitamin B12 deficiency associated with atrophic gastritis.
Biochem Genet
; 47(9-10): 645-50, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19521764
11.
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Leuk Lymphoma
; 64(10): 1715-1718, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37417467
12.
MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
Leuk Res
; 31(12): 1669-74, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17512587
13.
No evidence for fetal microchimerism in the skin of patients with pemphigoid gestationis.
Eur J Dermatol
; 20(1): 122-3, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19840915
14.
Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population.
Haematologica
; 89(2): 139-44, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15003888
15.
Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients.
Leuk Lymphoma
; 45(10): 2063-70, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15370251
16.
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Leuk Lymphoma
; 60(14): 3565-3568, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31286780
17.
Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Leuk Lymphoma
; 48(10): 2054-7, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17917973
18.
Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical-biological features of multiple myeloma.
Ann Hematol
; 85(7): 474-7, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16541270
19.
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Ann Hematol
; 84(11): 760-2, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16044311